Detalhe da pesquisa
1.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer
; 127(8): 1246-1259, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270904
2.
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Nat Med
; 29(4): 869-879, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37069359
3.
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Clin Cancer Res
; 27(18): 5020-5027, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253578
4.
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Nat Med
; 26(6): 878-885, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32451495
5.
Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.
Blood Adv
; 7(18): 5210-5214, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37327120